Guggenheim Capital LLC Acquires New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Guggenheim Capital LLC acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 106,094 shares of the biopharmaceutical company’s stock, valued at approximately $1,177,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Van ECK Associates Corp increased its stake in Amicus Therapeutics by 48.9% during the fourth quarter. Van ECK Associates Corp now owns 2,988 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 981 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Amicus Therapeutics by 33.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 3,807 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 953 shares during the period. First Horizon Advisors Inc. increased its stake in Amicus Therapeutics by 37.3% during the fourth quarter. First Horizon Advisors Inc. now owns 3,856 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 1,048 shares during the period. Point72 Middle East FZE purchased a new stake in Amicus Therapeutics during the fourth quarter worth about $81,000. Finally, Neo Ivy Capital Management acquired a new position in shares of Amicus Therapeutics during the fourth quarter worth about $121,000.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $12.92 on Friday. The stock has a 50 day moving average price of $12.94 and a 200 day moving average price of $12.27. The company has a quick ratio of 2.40, a current ratio of 2.72 and a debt-to-equity ratio of 3.53. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of -20.19 and a beta of 0.84. Amicus Therapeutics, Inc. has a 52-week low of $9.10 and a 52-week high of $14.10.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The business had revenue of $94.50 million during the quarter, compared to analyst estimates of $89.57 million. Amicus Therapeutics had a negative net margin of 52.85% and a negative return on equity of 157.79%. Research analysts predict that Amicus Therapeutics, Inc. will post -0.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.20.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, Chairman John F. Crowley sold 6,044 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $13.04, for a total value of $78,813.76. Following the completion of the sale, the chairman now owns 950,273 shares in the company, valued at $12,391,559.92. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 11,700 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $12.31, for a total value of $144,027.00. Following the sale, the chief executive officer now owns 815,154 shares of the company’s stock, valued at $10,034,545.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman John F. Crowley sold 6,044 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $13.04, for a total value of $78,813.76. Following the completion of the sale, the chairman now directly owns 950,273 shares in the company, valued at approximately $12,391,559.92. The disclosure for this sale can be found here. Over the last quarter, insiders sold 108,629 shares of company stock worth $1,445,385. 2.10% of the stock is owned by insiders.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.